VUB11_FXS

General

Cell Line

hPSCreg name VUBe011-A
Cite as:
VUBe011-A (RRID:CVCL_9848)
Alternative name(s)
VUB11_FXS
Cell line type Human embryonic stem cell (hESC)
Similar lines
RGIe041-A
(SI-125)
Donor diseases:
Fragile X syndrome
INSRMe005-A
(STR-I-189-FRAXA)
Donor diseases:
Fragile X syndrome
VUBe013-A
(VUB13_FXS)
Donor diseases:
Fragile X syndrome
RGIe116-A
(SI-214)
Donor diseases:
Fragile X syndrome
HADe005-A
(HAD 5)
Donor diseases:
Fragile X syndrome
INSRMe016-A
(STR-I-347-FRAXA)
Donor diseases:
Fragile X syndrome
HUJIe001-A
(HEFX1)
Donor diseases:
Fragile X syndrome
WISi006-A
(FX1 iPSC)
Donor's gene variants:
FMR1
Donor diseases:
Fragile X syndrome
INSRMe002-A
(STR-I-233-FRAXA)
Donor diseases:
Fragile X syndrome
Last update 15th October 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Vrije Universiteit Brussel (VUB)
Derivation country Belgium

External Databases

Cellosaurus CVCL_9848
Wikidata Q54993397

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is affected.
Synonyms
  • FXS
  • FraX syndrome
  • Martin-Bell syndrome
  • FRAXA syndrome
show more synonyms

Ethics

Was the embryo established purely for research purposes? No
Have both parents consented to the use of the embryo for ESC derivation? Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Alternatives to consent are available? Yes
Alternatives to consent
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Federal Commission Medical and Scientific Research on embryos in vitro (Belgium)
Approval number

hESC Derivation

Date of derivation 2006-09-19
Embryo stage Blastula with ICM and Trophoblast
Supernumerary embryos from IVF treatment?
No
Other hESC source: IVF
PGD Embryo?
Yes
Cell isolation Immunosurgery
Cell seeding Isolated ICM

Culture Conditions

Surface coating MEF
Feeder cells mouse embryonic fibroblast cell
Cellfinder Ont Id: EFO_0004040
O2 Concentration 20 %
CO2 Concentration 10 %
Medium Other medium:
Base medium: Knockout-DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
L-Glutamine
bFGF

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
SSEA-1
No
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
DNMT3B
Yes
GDF3
Yes
LIN28
Yes
NANOG
Yes
NPM1
Yes
POU5F1 (OCT-4)
Yes
ZFP42 (REX-1)
Yes
SOX2
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XX
Passage number: 45

Other Genotyping (Cell Line)